Literature DB >> 8105212

Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura.

M Debré1, M C Bonnet, W H Fridman, E Carosella, N Philippe, P Reinert, E Vilmer, C Kaplan, J L Teillaud, C Griscelli.   

Abstract

Treatment of acute immune thrombocytopenic purpura (ITP) with intravenous immunoglobulin (IVIG) induces partial or complete responses, shown by transient or persistent increases in platelet count. The clinical benefit could be due to blockade of the Fc gamma receptor (Fc gamma R); platelets sensitised by IgG could not be cleared by cells of the reticuloendothelial system if Fc gamma R on these cells was blocked with IVIG. To find out whether this putative mechanism is correct, we treated twelve children who had acute ITP with intravenous infusions of Fc gamma fragments. Eleven children showed rapid increases in platelet counts to above the critical value of 50 x 10(9)/L, thereby avoiding major haemorrhagic risk. The response was stable in six patients and transient in five. No adverse reactions were observed. In responders who had detectable platelet-associated IgG before treatment (> 1500 IgG per platelet), platelet IgG fell substantially with treatment. Serum soluble CD16 (sCD16 or sFc gamma RIII) concentrations, measured in five children, showed transient or stable increases that correlated with the rise in platelet count. No sCD16 was detected in the Fc gamma preparation used. We conclude that the infusion of Fc gamma fragments is an efficient treatment of acute ITP in children. The efficacy of Fc gamma fragments strengthens the hypothesis that Fc gamma R blockade is the main mechanism of action of IVIG in ITP, although other immunoregulatory mechanisms triggered by the presence of increased sCD16 concentrations in serum could be involved in the clinical benefit observed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8105212     DOI: 10.1016/0140-6736(93)92000-j

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  90 in total

Review 1.  [Chronic idiopathic thrombocytopenic purpura. Current therapy concept and introduction to pathophysiologic, clinical and diagnostic aspects].

Authors:  A Böcher; F G Hagmann; H Kreiter
Journal:  Med Klin (Munich)       Date:  1998-12-15

2.  From black magic to science: understanding the rationale for the use of intravenous immunoglobulin to treat inflammatory myopathies.

Authors:  S Y Patel; D S Kumararatne
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

3.  A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation.

Authors:  D Nachbaur; M Herold; B Eibl; H Glassl; H Schwaighofer; C Huber; A Gächter; M Pichl; D Niederwieser
Journal:  Immunology       Date:  1997-02       Impact factor: 7.397

4.  Crystal structure of Fcγ receptor I and its implication in high affinity γ-immunoglobulin binding.

Authors:  Jinghua Lu; Jeff L Ellsworth; Nels Hamacher; Si Won Oak; Peter D Sun
Journal:  J Biol Chem       Date:  2011-09-29       Impact factor: 5.157

Review 5.  Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

Authors:  Björn Tackenberg; Falk Nimmerjahn; Jan D Lünemann
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 6.  A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.

Authors:  Robert M Anthony; Jeffrey V Ravetch
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

Review 7.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

Review 8.  Activating and inhibitory FcgammaRs in autoimmune disorders.

Authors:  Falk Nimmerjahn
Journal:  Springer Semin Immunopathol       Date:  2006-10-01

Review 9.  Facing the enigma of immunomodulatory effects of intravenous immunoglobulin.

Authors:  Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 10.  Targeting the Fc receptor in autoimmune disease.

Authors:  Xinrui Li; Robert P Kimberly
Journal:  Expert Opin Ther Targets       Date:  2014-03       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.